In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mirati Therapeutics Inc.

www.mirati.com

Latest From Mirati Therapeutics Inc.

Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks

Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.

Financing StartUps and SMEs

Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets

Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.

Financing Business Strategies

Pipeline Watch: Phase III Starts With VX-445, Reproxalap And AVXS-101

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry, February 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.

Deals Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • MethylGene Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mirati Therapeutics Inc.
  • Senior Management
  • Charles M Baum, MD, PhD, Pres. & CEO
    Jamie Donadio, SVP, CFO
    Isan Chen, MD, Chief Medical & Dev. Officer
    James Christensen, PhD, SVP, CSO
    Chris LeMasters, CMO
  • Contact Info
  • Mirati Therapeutics Inc.
    Phone: (858) 332-3410
    9393 Towne Centre Dr.
    Ste. 200
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register